Adjuvant Treatment Phase

Phase 2Protein / enzyme

Adjuvant Treatment Phase is one of 52 small molecule programs targeting Neoadjuvant Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoadjuvant TherapyRecruiting

Neoadjuvant TherapyPhase 2

Recruiting

Competition

Competitive Landscape

60 competitors in Neoadjuvant Therapy

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 3

2 2

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

5 3

Tuoyi

CCoherus Oncology, Inc.

Phase 3

2 4

Keytruda

Merck & Co.

Phase 2

5 5

Avastin

Roche

Phase 2

4 6

Beyfortus

BeiGene

Phase 2

4 7

Abraxane

Bristol-Myers Squibb

Phase 2

3 8

Eloxatin

Teva

Phase 2

2 9

Ellence

Pfizer

Phase 2

2 10

Tagrisso

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Neoadjuvant Therapy

NCT04875585

Clinical

Trials by Indication[1]

Neoadjuvant Therapy1 trial

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC

Recruiting·MMedical University Innsbruck·Phase 2·NCT04875585·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adjuvant Treatment Phase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adjuvant Treatment Phase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adjuvant Treatment Phase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University Innsbruck company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: MMedical University Innsbruck

Adjuvant Treatment Phase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Neoadjuvant Therapy1 trial

References

Drug Info

Quick Facts

Related News